How to Buy Coherus Biosciences Stock
Coherus Biosciences Inc
Coherus BioSciences, Inc. , a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States.
Coherus Biosciences stock last closed at $1.00, down 2.91% from the previous day, and has decreased 51.69% in one year. It has overperformed other stocks in the Biotechnology industry by 0.26 percentage points. Coherus Biosciences stock is currently +51.52% from its 52-week low of $0.66, and -58.85% from its 52-week high of $2.43.
At the moment, there are 115.9M CHRS shares outstanding. The market cap of CHRS is $115.90M. In the past 24 hours, 934,902 CHRS shares were traded.
How to Buy Coherus Biosciences Stock
Not sure how to invest in Coherus Biosciences stock? Here's how.
- Figure out where to buy Coherus Biosciences stock: You need to pick a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you choose where to buy Coherus Biosciences stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Choose your method of payment and add your information.
- Evaluate Coherus Biosciences stock: The Coherus Biosciences ticker symbol is CHRS. Is Coherus Biosciences stock a good investment? Should you buy shares of CHRS? How do CHRS's underlying business fundamentals look? Do top analysts think Coherus Biosciences is a good buy? Why has CHRS's stock price moved recently? (Hint: Our stock research website can help you evaluate if CHRS is a good stock to buy).
- Make your CHRS trade: Decide if you will purchase CHRS shares at the current market price or use a limit order to buy CHRS shares at a particular price.
- Keep tabs on your investment in CHRS: Create a watchlist to key updates about your position in Coherus Biosciences shares.
Step 1: Figure out where to buy Coherus Biosciences stock
You need a brokerage account in order to access the NASDAQ market and buy CHRS stock.
Our preferred brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal information so you are able to buy CHRS stock today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new trading account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have filled out your info on the greatest app to buy stocks, your next step is to transfer the money for your investment:
Check out the tutorial below to see the process of transferring funds into your investment account.
Step 4: Evaluate Coherus Biosciences stock
Once you have decided on the best place to buy Coherus Biosciences stock, it's absolutely critical to analyze their stock before you invest, so you truly wrap your head around the risk and upside.
Coherus Biosciences Numbers
Coherus Biosciences Due Diligence Checks
WallStreetZen was designed to help part-time investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CHRS's stock page.
Is CHRS stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CHRS's true value.
Using relative valuations measures:
- CHRS may be undervalued based on its P/E ratio of 4x, relative to Biotechnology industry P/E ratio of -158.75x
You can do more valuation analysis on CHRS's stock here.
How do CHRS Financials look?
Pros:
- CHRS has $125.99M in cash and short term investments. This is sufficient to cover its annual cash burn of $20.44M.
- There are more short-term assets than long-term liabilities on the CHRS balance sheet.
- There are more short-term assets than short-term liabilities on the CHRS balance sheet.
- CHRS profit margin has gone up from -92.5% to 10.7% in the past year.
- CHRS has cash burn of 20440000. It has enough cash and short-term investments to cover this for at least one year.
Cons:
- Total CHRS debt is still negative.
- CHRS debt to equity ratio of -4.4 is negative.
Is Coherus Biosciences stock a Buy, Hold, or Sell, according to analysts?
Out of 3 Wall Street analysts who give forecasts on CHRS, the consensus analyst rating on CHRS is a Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are saying on the Coherus Biosciences stock forecast page.
CHRS Technical Indicators
CHRS Performance Metrics
Last year, CHRS earnings were $28.51M. During the past 5 year, CHRS's earnings have gone up by -27.98% per year. This was slower than the Biotechnology industry average of 10.52%.
Last year, CHRS revenue was $266.96M. In the last 5 year, CHRS's revenue has gone up by -5.6% per year. This was slower than the Biotechnology industry average of 45.47%.
Learn more about CHRS's earnings and revenue performance here.
Latest Insiders Trades at CHRS
In the past 12 months, executives and large shareholders at CHRS have sold more shares than they have bought.
Dennis M. Lanfear, President CEO of CHRS, was the latest CHRS insider to sell. They sold $16,415.90 worth of CHRS stock on Jan 20, 2025.
Research more about who owns CHRS stock here.
Can I rely on CHRS as an income stream?
No, Coherus Biosciences doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your CHRS trade
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally the best for newer investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at an exact dollar amount limit, use a limit order.
Press the Open button and eToro will execute the order.
If you want additional help with buying stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your investment in CHRS
Now that you own some CHRS stock, you'll want to keep up with your new investment.
Create a watchlist to get notified of important updates regarding your CHRS stock.
CHRS Feed
How to Buy Stock in Coherus Biosciences
To summarize, here are the 6 steps you need to take to buy Coherus Biosciences stock right now:
- Figure out where to buy Coherus Biosciences stock
- Sign up for your brokerage account
- Deposit funds into your investment account
- Evaluate Coherus Biosciences stock
- Make your CHRS trade
- Keep tabs on your investment in CHRS
If you are looking for a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to watch your investment in Coherus Biosciences, click below.
Other "How To" Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.